Roche

Dec 24, 2020

NIH awards USD 107 Million for radical COVID-19 testing tech  The National Institutes of Health (NIH) awarded over USD 107 million for radical approaches to testing for COVID-19 and tracing the spread of the disease, including cutting-edge technologies, which could make daily coronavirus testing less interf...

Dec 03, 2020

Roche receives FDA authorization for the quantitative COVID-19 antibody test Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. The company anticipates the tes...

Oct 20, 2020

Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia   The US FDA has granted its full approval to Venclexta (venetoclax) for newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older who are unfit for intensive induction chemotherapies.  The approval is based on the res...

Oct 15, 2020

Cyclerion flunks sickle cell test, prompting pivot to CNS disease Cyclerion Therapeutics has terminated the development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial. The setback caused Cyclerion to switch its focus to IW-6463 and to treat central nervous system diseases....

Sep 24, 2020

J&J commences COVID-19 vaccine phase 3 Johnson & Johnson has begun a 60,000-subject phase 3 evaluation of its COVID-19 vaccine. The trial will enroll participants in the U.S. and other countries with a high incidence of COVID-19 to generate data to bolster emergency use authorization early next year. ...

Aug 18, 2020

New strategy, new outlook: Sanofi takes another step, gains full control over the Principia’s MS treatment  Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected t...

Aug 13, 2020

Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead’s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Bla...

Aug 11, 2020

Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy  The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Genentech, a Roche company, for spinal muscular atrophy (SMA), an inherited neuromuscular disease resulting in muscle atrophy, in adults and...

Aug 10, 2020

ATS 2020 Virtual is scheduled to be held from August 5 to August 10, and it is exciting to watch the key presentations by Pharmaceutical Companies specifically focused on pulmonary disease, critical illness, and sleep disorders. Boehringer Ingelheim presented new analyses of Ofev data in patients with chronic fi...

Jul 30, 2020

Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...